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Abstract
Background: Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate
cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple
cancer cell lines. However, how and to what extent CPA-7 elicits its anti-prostate cancer effects in vivo is largely unknown.
Methods: In this study, we firstly assessed the potential toxicity of the synthesized CPA-7 in a prostate cancer model as
well as in normal mice. Next, we evaluated the in vitro effects of CPA-7 on the growth of prostate cancer cells using cell
counting assay, and calculated the tumor sizes and cumulative survival rate of the tumor bearing mice by Kaplan-Meier
method during CPA-7 treatment. Then we measured the expression level of the activated form of STAT3 (one targets of
CPA-7) and its transcriptive activity post CPA-7 treatment by synergistically using western blot, IHC, and firefly luciferase
reporter assays. Finally, effects of CPA-7 on immune cell trafficking in the tumor draining lymph nodes and in the spleens
are evaluated with flow cytometry.
Results: Treatment with CPA-7 significantly inhibited growth of prostate cancer cells in vitro, and also in mice resulting in
a prolonged survival and a decreased recurrence rate. These therapeutic effects are due, at least in part, to functional
depletion of STAT3 in prostate tumor tissue as well as in the surrounding areas of tumor cell invasion. CPA-7 treatment
also resulted in a reduced level of regulatory T cells and increased levels of cytotoxic T and T helper cells in the spleen
and in tumor infiltrating lymph nodes. This favorable effect on immune cell trafficking may account for the amnestic
immune response against recurrent prostate cancer.
Conclusions: CPA-7 is a promising new therapeutic agent for prostate cancer that both inhibits tumor cell proliferation
and stimulates anti-tumor immunity. It has potential as first line treatment and/or as an adjuvant for refractory prostate
cancer.
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Background
Androgen deprivation therapy (ADT) is used as a first
line therapy for hormone sensitive, metastatic prostate
cancer (PC). ADT acts by depleting testosterone levels,
leading to substantial cancer control and palliation lasting
an average of 20–30 months [1, 2]. However, when
prostate cancer has progressed to the castrate resistant
stage and is no longer expected to respond to treatment
with ADT, the first line of treatment is typically with a
platinum compound such as carboplatin, cisplastin, oxali-
platin or satraplatin, combined with docetaxel or etopo-
side [3, 4]. These combined treatments have recently
shown promising results, especially for neuroendocrine
prostate cancers which are usually resistant to androgen
deprivation therapies [4, 5]. Among the family of platinum
(IV)-based compounds, a member known as CPA-7 with
a molecular formula of fac-[PtCl3(NO2)(NH3)2] induces
apoptosis in multiple cancer cell lines, including human
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breast, lung, colon and prostate cancer cells and in mouse
melanoma cells [6, 7]. However, how and to what extent
CPA-7 elicits its anti-prostate cancer effects in vivo is
largely unknown.
Signal transducer and activator of transcription 3
(STAT3) is, with phospho-STAT3 (pSTAT3) as its acti-
vated form, an important oncogenic protein well known
for its role in tumor cell proliferation, survival, and inva-
sion. Constitutively activation of STAT3 is found in ap-
proximate 70 % of the solid malignancies, including
hematological malignancies as well as diverse solid tumors
such as head and neck, breast, lung, gastric, hepatocellular,
colorectal and prostate cancers [8, 9]. In prostate cancer,
aberrant IL-6/STAT3 signalling is one of the most involved
pathways during the transition of metastatic disease [10].
In addition to directly function on tumor cells, STAT3 also
plays pivotal roles in anti-cancer immunity, not only as a
potent negative regulator of T helper 1 (TH1)-cell-medi-
ated inflammation, but also as an important activator of
genes that are crucial for immunosuppression [11]. There-
fore, targeting STAT3 could well reduce tumorigenesis
and modulate tumour-induced immunosuppression.
To date, STAT3 specific inhibitor is still under devel-
opment [12]. Among the STAT3 inhibitors, such as
SHP2, HJC0152, Benzyl isothiocyanate [13], CPA-7 was
found efficiently targeting STAT3 [7, 14]. At low doses,
CPA-7 depletes the DNA binding capacity of STAT3
leading to down-regulation of genes down-stream of
STAT3 and, ultimately, to tumor regression [7]. Another
study reported that functional depletion of STAT3 elic-
ited by CPA-7 treatment resulted in down-regulation of
IL-10 and IL-6, and up-regulation of IL1-β in glioma
cells [15]. In addition to STAT3, report from Assi H
demonstrated that CPA-7 also inhibited the activity of
STAT1 and NF-kB, as evidenced by the firefly luciferase
assays [16], suggesting the pleiotropic effects of CPA-7.
However, STAT3 may possibly account for the most sen-
sitive one because CPA-7 induced functional depletion
of STAT3 at very low concentration. In prostate cancer,
the in vivo effects of CPA-7 on STAT3 and accordingly
on immune profile are still need to be clarified.
To address the questions above, in the present study, we
first assessed the potential toxicity of CPA-7 in vivo. In
addition, we evaluated the effects of CPA-7 on the growth
of prostate cancer cells in vitro and in vivo, and its effects
on immune cell trafficking. Finally, we measured the effects
of CPA-7 on the expression level of the activated form of
STAT3 and its transcriptive activity post CPA-7 treatment.
Methods
Antibodies, reagents and kits
Rabbit anti-mouse p-STAT3 antibody (Y705) was pur-
chased from Cell Signaling (USA). HRP-conjugated goat
anti-rabbit antibody and Mouse Regulatory T Cell
Staining Kit were from eBioscience (USA). Rabbit anti-
mouse-CD8 antibody was from BD Pharmingen (USA).
ABComplex/HRP (Rabbit IgG, Cat SK-5100), AEC sub-
strate kit (SK-4200), 3-amino-9-ethylcarbazole, and nor-
mal goat serum were from Vector Laboratories (USA).
Fugene HP transfection reagent was from Roche Applied
Science (USA). STAT3 Luciferase Reporter Vector was
from Beyotime (China). pRL-TK vector was from Pro-
mega (USA). Firefly & Renilla Luciferase Assay Kit was
from Biotium Inc (USA). All of the other reagents were
from Sigma Aldrich (USA) except indicated.
Cell line
Murine prostate cancer cell line RM-9 was a gift from
Dr. Mouraviev in Duke University and was grown at 37 °C
in complete Dulbecco’s Modified Eagle Medium (DMEM,
Life Technologies, USA), supplemented with 10 % fetal
bovine serum (Biological Industries, Israel), 2 mM L-glu-
tamine, 50 IU/mL penicillin and 50 μg/mL streptomycin
(Life Technologies, USA) and in a humidified atmosphere
of 5 % CO2 and air. HEK293T cells, which were from
American Type Culture Collection (ATCC, USA) and
used for the luciferase reporter assay, were cultured in the
same conditions as the RM-9 cells.
CPA-7 synthesis
CPA-7 was synthesized as previously described [6].
Briefly, 300 mg of yellow sis-[PtCl2(NH3)2] (0.1 mmol)
was suspended in a solution of 0.074 g KCl (0.1 mmol)
in 25 ml distilled water. The mixture was protected from
light by aluminum and stirred, while bubbling nitrogen
dioxide through the solution at a rate of approximately
one bubble per second. The cylinder of NO2 was
warmed in a water bath at ~45 °C in order to increase
the vapor pressure of the gas. When the reaction mix-
ture was completely dissolved to form a dark turquoise
solution, NO2 bubbling was terminated and air was bub-
bled through the solution overnight. The following day,
if the solution remained yellow, the reaction was consid-
ered complete and the mixture was pumped with vac-
uum dryer to dryness. The yellow powder was collected
and stored at −80 °C until use.
Cell counting
RM-9 cells were seeded into 24-well plates at 2 × 104
cells/well and incubated overnight at 37 °C. Then cells
were treated daily with fresh culture medium containing
either CPA-7 at concentrations of 5, 10 or 20 μM or
with 1 % DMSO, the vehicle control. At each treatment,
the cells in 3 parallel wells per conc of CPA-7 or DMSO
were collected by trypsinization. Suspended cells from
individual wells were diluted in trypan blue exclusion
medium and counted with the use of a haemocytometer.
Trypan blue stained cells were considered non-viable.
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The total number of viable cells in each group were
recorded.
Western blot
RM-9 cells were seeded into 6-well plates at 5 × 105
cells/well and treated with either CPA-7 at 10 μM or
1 % DMSO vehicle for 24 h. The cells were collected by
trypsinization and washed twice with cold PBS. Total
protein was extracted by adding RIPA buffer to the cell
and sonicating the mixture on ice. The lysate was centri-
fuged at 14,000 g, 4 °C for 30 min and the supernatant
was collected. An amount of 40 μg of total protein was
separated on a 12 % SDS-PAGE gel and transferred onto a
PVDF membrane. Then the membrane was immersed in
PBS containing 5 % fat-free milk for 4 h at room
temperature. Primary antibody was added into the block-
ing buffer at 1:500 dilution overnight at 4 °C. After the
membrane was washed with TBS-T buffer, secondary anti-
body was applied at 1: 2000 dilution in blocking buffer for
another one hour. After washing with TBS-T buffer, the
membrane was incubated with luminol substrate solution
(Transgene, China). Signal of the target protein was sensi-
tized and developed with an X-ray film.
Firefly and Renilla Luciferase assay
RM-9 cells were seeded into 12-well plates one day
before transfection. When cell growth was ~50 %
confluent, transfections were performed. Briefly, for
each well, 1 μg of pSTAT3-Luc vector plus 0.05 μg
pRL-TK vector (background control) were mixed with
Opti-Medium and incubated for 10 min at room
temperature, followed by addition of 2.5 μl FuGene
HD transfection reagent. After incubation for another
15 min, the transfection complex was added to each
well and the plate returned to the incubator. Twenty-
four hours post transfection, the cells were treated
with culture medium containing CPA-7 at 5 μM,
10 μM or 1 % of vehicle-DMSO. After another 24 h,
cells were collected and Luciferase assay was per-
formed following the manufacturers instructions. In
brief, cells were treated with lysis buffer for 15 min.
After centrifugation, 10 μl of supernatant plus 50 μl
of firefly luciferase assay solution was mixed together
in a luminometer tube. Then the firefly luciferase ac-
tivity was measured with a luminometer. Secondly,
10 μl of supernatant was added into a new tube to
which was added 25 μl of Renilla Luciferase Assay
Enhancer followed by 25 μl of Renilla Luciferase
Assay Solution. This complex was then measured
with the luminometer to determine the background
fluorescence which served to normalize the transfec-
tion and the amount of protein loaded.
Tumor model and CPA-7 treatments
C57BL/6 J mice, 6–8 weeks old, were purchased from
Vital River (Beijing, China) and housed in the vivarium.
All the animals were handled in accordance with the
established animal care policy and all animal experi-
ments were approved and supervised by the Harbin
Medical University Institutional Animal Care & Use
Committee. As indicated in the Study Design (Fig. 1a),
Fig. 1 Study design and side effects of CPA-7 for in vivo treatment evaluated by body weight. a, schematic illustration of the study design. CPA-7
was administrated by tail vein injection at three different doses. Injection of PBS containing 1 % DMSO (vehicle) served as control. An additional
three groups of animals were used to evaluate tumor recurrence. These mice were subjected to surgical ablation two days post CPA-7 treatment
and followed up for total of 60 days. b, effects of CPA-7 treatment on body weight in RM-9 tumor bearing mice. n = 9 ~ 11 for each group. c, effects of
CPA-7 treatment on body weight in tumor bearing mice after surgery. n = 10 ~ 12 for each group. d, effects of CPA-7 treatment on body weight in
healthy mice. n = 10 for each group. *, P < 0.05, **, P < 0.01, ***, P < 0.001 when compared with vehicle group
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RM-9 tumor model was established by subcutaneously
injecting 8 × 104 RM-9 cells into the right hind limb of
each mouse. Tumors were allowed to grow for about
7 days until they reached 5 ~ 6 mm in diameter before
administration of CPA-7 every three days via tail vein
injection. The animals were checked for tumor devel-
opment for 30 days. During this period the tumor vol-
umes and sizes, and the body weights were recorded
daily. The humane endpoints were defined by overall
tumor volume exceeding 2 × 103 mm3 or when the tu-
mors developed ulcers.
In a parallel experiment to determine anti-tumor
memory following treatment with CPA-7, two days fol-
lowing the first administration of CPA-7 or sham treat-
ment, the primary tumor along with the skin above the
tumor tissue was surgically removed. Animals were con-
tinuously subjected to CPA-7 treatment and regarded as
completely recovered from surgery and free of recur-
rence when no local tumor was observed four weeks
after surgery [17]. Rechallenge was performed 30 days
after surgery in recurrence free animals. A total of 5 × 103
RM-9 cells were subcutaneously injected into the contra-
lateral limb of the mouse. The animals were then followed
for another 30 days, during which the tumor recurrence
and survival rate were recorded.
Flow cytometry
Three and twelve days post CPA-7 treatment, three
mice in each group were randomly euthanized and the
spleens and tumor draining lymph nodes (TDLNs) were
harvested for flow cytometry. Briefly, single cell suspen-
sions from pooled spleens or TDLNs (1 × 106/staining)
were prepared and FcγR was blocked for 15 min by
CD16/32 antibody (Fc Block) before cell surface stain-
ing. Following cell surface staining of CD4 and CD25,
intracellular staining of Foxp3 to identify Tregs was
performed with fixation/permeabilization working solu-
tion (eBioscience). The stained cells were processed
with a FACS Aria II flow cytometer (BD, USA). Tregs
were identified by CD4+Foxp3+ markers. Cytotoxic T
lymphocytes are represented as CD8+ population in
spleen and TDLN.
Immunohistochemistry (IHC)
Three and twelve days after CPA-7 treatment, three
mice from each group were sacrificed. The tumor tissues
were collected and fixed overnight with 10 % formalin.
After embedded in paraffin, tissues were cut at 5 μm
thickness and mounted to glass slides. The tissue sec-
tions were deparaffinized, rehydrated, and subjected to
antigen retrieval in an EDTA-containing buffer for
30 min at 95 °C. Endogenous peroxidase activity was
blocked with 0.3 % hydrogen peroxide for 15 min at
room temperature. Then the slides were incubated
with 10 % normal goat serum for 30 min and then with
rabbit anti-mouse phospho-STAT3 antibody (diluted
with PBS at 1:50) at 4 °C overnight. Following washes
with PBS, the slides were incubated with biotinylated
secondary antibodies (diluted with PBS at 1:200) for
30 min at room temperature and then with avidin-
biotin-horseradish peroxidase complex for another
30 min. Detection was performed using 0.125 % ami-
noethylcarbazole chromogen. After counterstaining with
Mayer’s hematoxylin (Sigma), the slides were mounted.
Under microscope, nuclei of phospho-STAT3 positive
tumor cells were in purple, while nuclei of phospho-
STAT3 negative cells remained in blue. Scoring was
conducted by evaluating at least 10 different fields per
sample and independent observations by three different
pathologists.
Statistical analysis
Comparison between the observation and the control
groups was carried out mostly by using the Student’s
t-test with the results expressed as mean ± SD. The cu-
mulative survival rate was calculated by using the
Kaplan-Meier method and difference in the survival
rate was evaluated by the log-rank test using Softstat soft-
ware. P < 0.05 was considered to be statistically significant.
Results
Synthesized CPA-7 had little impact on the body weight
of the mice when applied at no more than 1.5 mg/kg
Because side effects are a major concern with platinum-
based antineoplastics, we evaluated the safety of CPA-7.
RM-9 tumor bearing mice were treated initially with two
doses of CPA-7 administered by tail vein injection when
the tumor size reached 5 mm in diameter. Vehicle (1 %
DMSO in PBS) injected mice were used as controls. All
three groups of mice were weighed every three days and
each mouse given 8 separate injections. As shown in
Fig. 1b, the body weights of mice treated with either
0.75 mg/kg or 1.5 mg/kg CPA-7 increased slightly with
time throughout the entire period of observation. Body
weight differences between vehicle control and CAP-7
treated mice were not statistically different although the
mice treated with 1.5 mg/kg of CPA-7 were lighter than
mice in the other two groups during most of the follow-
up period. Since the ever-growing tumor mass may com-
pensate the loss of body weight resulted from CPA-7
treatment, we next surgically removed the tumors 2 days
after CPA-7 injection and continued the follow-up to
the end point. As shown in Fig. 1c, mouse weights in the
CPA-7 treated groups are not statistically different from
those in the control group.
To rule out the impact of tumor burden and surgery
on body weight, we next tested the safety of CPA-7 in
healthy mice with an additional higher dose of 3.8 mg/kg,
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which is equivalent to 10 μM/kg. Similar to results ob-
tained in tumor bearing mice, healthy mice subjected to
1.5 mg/kg of CPA-7 had steady increases in body
weight. However, when the CPA-7 dose was increased
to 3.8 mg/kg, we observed significant reductions in
body weight after the 4th (day 15) injection as com-
pared with the control group. Though the weight
promptly returned to the basal level 3 days after ter-
mination of CPA-7 injections, statistical significances
between the group treated at 3.8 mg/kg and the control
group continued over the observation from the time
point of 4th injection on which the differences initially
occurred (Fig. 1d).
Synthesized CPA-7 inhibits RM-9 cell growth in vivo and
in vitro
In order to determine to what extent our synthesized
CPA-7 is capable of inhibiting tumor growth, RM-9 cells
were treated with CPA-7 at various concentrations, and
the vehicle DMSO was used as control. As seen in Fig. 2a,
the number of RM-9 cells treated with 5 or 10 μM CPA-7
decreased over time whereas the number of DMSO-
treated control cells increased significantly (P < 0.001) be-
ginning with day 2 post-treatment. CPA-7 at 10 μM had a
stronger tumor inhibitory effect than at 5 μM. Seven days
after treatment, the number of the cells in cultures treated
with 10 μM CPA-7 was approximately the same as the
starting number, compared with nearly half the number of
the primary cells in cultures treated with 20 μM of CPA-7.
Overall, it is apparent that CPA-7 strikingly inhibits prolif-
eration of RM-9 cells.
We next evaluated the ability of CPA-7 to inhibit the
growth of RM-9 tumors in vivo. As seen in Fig. 2b, on
Day 0, on which was the initial treatment of the mice
with either CPA-7 or the vehicle control, the tumor sizes
were similar in all groups. Thereafter, tumors in mice
treated with CPA-7 were smaller than those in vehicle
control animals. CPA-7 at 1.5 mg/kg elicited the stron-
gest tumor inhibitory effect, followed by CPA-7 at
0.75 mg/kg. After 18 days, which was the 7th treatment
cycle, RM-9 tumors in mice treated with 1.5 mg/kg
CPA-7 (1167 ± 228 mm3) were found to be significantly
Fig. 2 Therapeutic effects of CPA-7 on RM-9 tumor. a, cell counting assay using in vitro cultured RM-9 cells. ***, P < 0.001 when compared with
the vehicle control. b, dynamic curve of tumor sizes during follow-up. The tumor bearing mice were monitored for 30 days, during which tumor
sizes were recorded every three days. n = 12 ~ 15 for each group. *, P < 0.05 when compared with the vehicle group. c. Kaplan-Meier plots for
overall survival. Tumor bearing mice were treated with CPA-7 at indicated doses or with vehicle and monitored for 30 days. n = 11 ~ 12 for each
group. CPA-7 treatment at 1.5 mg/kg significantly prolonged the overall survival of the animals when compared with the vehicle group (*, log-
rank P = 0.036). CPA-7 treatment at 0.75 mg/kg also had a trend to prolong the overall survival of the tumor bearing mice (log-rank P = 0.051). d,
impact of CPA-7 on median survival time and survival rate at the end of follow-up. Both median survival time (left Y axis) and survival rate (right Y axis)
were calculated in the end of the follow-up and plotted to different dose of CPA-7. Each group had 11 ~ 12 mice. *, P < 0.05 when compared with the
vehicle group
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(P < 0.05) inhibited in size relative to the control group
(1958 ± 375 mm3) whereas those in mice treated with
0.75 mg/kg CPA-7 (1710 ± 417 mm3) were not statisti-
cally different from the control group (P ≥ 0.05). Log-
rank analysis demonstrated that during the observation
period, tumor bearing mice subjected to 1.5 mg/kg
CPA-7 (P = 0.036), but not 0.75 mg/kg, had significantly
higher survival time than vehicle controls, though dose
of 0.75 mg/kg showed a trend to increase the survival of
the tumor model (Fig. 2c). At the end of the follow-up,
both doses led to significantly higher median survival
time and survival rate when compared with the control
group (Fig. 2d), and the high concentration of CPA-7 led
to higher survival rate than low concentration, while no
statistical significance was found between the two CPA-
7 treated groups (Fig. 2d). To determine the effects of
CPA-7 on tumor recurrence, primary tumors were sur-
gically removed two days after the starting point of
CPA-7 treatment. Thirty days post surgery, the ani-
mals were re-challenged with 5000 RM-9 cells admin-
istered sub-q into the contralateral limb and followed
for another 30 days. At the end of the observation
period, mice treated with both concentrations of CPA-
7 were found to have significantly (P < 0.05) lower re-
currence rates (6 out of 12 in the 0.75 mg/kg CPA-7
treatment group and 4 out of 12 in the 1.5 mg/kg
CPA-7 group) when compared with the vehicle control
group (9 out of 12).
CPA-7 down-regulates the activity of STAT3 in vivo and in
vitro
We previously reported the content of endogenously
expressed activated form of signal transducer and activa-
tor of transcription 3 (phospho-STAT3, p-STAT3) in
prostate cancer cells [18]. In the present study, we found
that CPA-7 depletes p-STAT3 in cultured RM-9 cells as
revealed by Western blot analysis (Fig. 3a). Expression of
p-STAT3 was effectively depleted by 10 μM CPA-7 as in-
dicated when comparing the second lane with the first
lane in the second uppermost panel. In addition, as
shown in the uppermost panel, total STAT3 level in
RM-9 cells changed only slightly post CPA-7 treatment.
These results indicate the CPA-7 doesn’t affect the ex-
pression of total STAT3, but deregulates its activity. The
significant down-regulation of Bcl-xL, one well docu-
mented target of pSTAT3, further verified the functional
depletion of STAT3 after CPA-7 treatment. To further
determine the effect of CPA-7 on STAT3 transcriptional
activity, luciferase assays were performed using pGAS-
Luc transfected HEK293 cells expressing a luciferase
gene construct under control of a Stat3-specific pro-
moter. HEK293 cells were treated with CPA-7 at 5 and
10 μM for 24 h after which their total proteins were ex-
tracted and luciferase activity was measured. As shown
in Fig. 3b, treatment with 10 μM CPA-7 caused approxi-
mately a 32 % reduction in STAT3 activity when com-
pared with the negative control, which represented the
endogenous STAT3 activity. Treatment with 5 μM CPA-
7 led to a 23 % reduction in STAT3 activity.
Next, we determined whether CPA-7 inhibits STAT3
activity in the RM-9 tumor model, CPA-7 was injected
in the tail vein at final concentrations of either 0.75 or
1.5 mg/kg. Three days after administration, primary tu-
mors were removed and p-STAT3 measured by immu-
nohistochemistry (IHC) [18]. As shown in Fig. 3c and
d, it is apparent that CPA-7 treatment can significantly
(P < 0.01) reduce the level of pSTAT3 in RM-9 tumor
tissue in a dose dependent manner, where CPA-7 treat-
ment at even the low dose of 0.75 mg/kg led to more than
a 3.6-fold decrease in the pSTAT3 level (Fig. 3c, P =
0.005). Likewise, pSTAT3 level was strikingly down-
regulated on Day 12 during the CPA-7 treatment
(Additional file 1: Figure S1). In addition to the cen-
tral region of tumor tissues, sections prepared from
the tumor boundary were also subjected to IHC to-
wards pSTAT3. As anticipated, before CPA-7 treat-
ment, the level of p-STAT3 was high in the infiltrating
area between the tumor tissues and the adjacent muscle tis-
sues. Statistically significant inhibition (P < 0.05) of pSTAT3
was found after CPA-7 treatment when compared to
the vehicle control (Fig. 3e). The inhibiting indexes in
tumor boundary were compatible with the inner tumor
tissue. These results clearly indicate that CPA-7 inhibits
the pSTAT3 level in vivo.
CPA-7 treatment improves the anti-tumor immune re-
sponse in mice
Regulatory T cells (Tregs) account for a small fraction of
CD4+ T cells but inhibit immune responses and have
been implicated in immune tolerance to tumors [19]. In
contrast, CD8+ cytotoxic lymphocytes recognize and
eradiate tumor cells [20]. To investigate whether CPA-7
treatment at dose of 0.75 mg/kg or 1.5 mg/kg affects T
cell subsets, single lymphocyte suspensions were pre-
pared from spleens and tumor infiltrating lymph nodes
(TDLNs) at 3 and 12 days after the first treatment of
CPA-7. The cell suspensions were stained using anti-
CD8, anti-CD4 and anti-FOXP3 antibodies and analyzed
by flow cytometry. Three days after CPA-7 treatment
with either dose, the number of CD4+ cells in the spleen
increased more than 1.9 fold when compared with the
vehicle control (Fig. 4a, p < 0.05 for CPA-7 at 0.75 mg/
kg and p < 0.001 for CPA-7 at 1.5 mg/kg). In addition,
the number of CD8+ cells in the spleen increased about
1.7 folds in animals treated with 1.5 mg/kg CPA-7 (Fig. 4b,
p < 0.001), while the low-dose of CPA-7 only marginally
changed the number of CD8+ cells. In contrast, the num-
ber of splenic Treg cells was significantly decreased post
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treatment with CPA-7 at either dose (Fig. 4c; 33 % reduc-
tion for CPA-7 at 0.75 mg/kg, p < 0.05; and a 44 % reduc-
tion for CPA-7 at 1.5 mg/kg, p < 0.05). For the TDLNs
treatment with 0.75 mg/kg CPA-7 resulted in a non-
significant decrease in Treg cells whereas treatment with
1.5 mg/kg resulted in a significant 20 % decrease in Treg
cells (Fig. 4d, p < 0.001). Similar but more consistent
changes in the immune profile were found at Day 12
during the course of CPA-7 treatment (Fig. 4e-h). These
results suggests that after CPA-7 treatment there is a long-
lasting increase in cytotoxic T cells and a decrease of Tregs
in spleen as well as in TDLNs after CPA-7 treatment.
Discussion
The progression of prostate cancer to castration resist-
ance results in a significant shortening of the anticipated
survival period and limited treatment regimens. In spite
of the significant progress in anticancer drug develop-
ment for patients with metastatic castration-resistant
prostate cancer in the past few decades, conventional
chemotherapies are still widely used for prostate cancer
worldwide [21, 22]. However, clinical application of con-
ventional chemotherapeutic drugs including platinum-
based chemicals is significantly thwarted by numerous
undesirable side effects such as severe kidney problems,
Fig. 3 Inhibitory efficacy of CPA-7 on STAT3 activity. a, functional depletion of activated STAT3 in RM-9 cells. RM-9 cells were incubated for 24 h
with CPA-7 at the indicated doses or vehicle containing 1 % DMSO, respectively. Total protein was isolated and thereafter western blot was
performed against STAT3, pSTAT3, and Bcl-xL. Immunobloting against β-tubulin was included as control. b, transcriptive activity of STAT3
determined by luciferase reporter assay. HEK-293 T cells were maintained and transfected with vectors as indicated in the Materials and Methods.
After CPA-7 or vehicle treatment, total protein was extracted and STAT3 specific firefly luciferase activity was determined, with normalization to
renilla luciferase activity. c, d and e, in vivo level of pSTAT3 after CPA-7 treatment. pSTAT3 positive cells were calculated by individually counting
three different random microscope fields in the central regions of the tumor tissues (d) or in the infiltrating areas (e). Percentage of positive rate
in the central region of the tumor tissues was obtained by dividing each number with the total number of cells in the corresponding field (c). *,
P < 0.05, **, P < 0.01, ***, P < 0.001 when compared with the vehicle group
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allergic reactions, hemorrhage, and hearing loss [23]. Re-
cently, chemicals that possess the potential of modulating
anti-tumor immunity have gained significant attention for
cancer treatment [22, 24, 25]. For example, Low-dose dec-
itabine treatment recruit NK and CD8+ T cells, promotes
their production of IFNγ and TNFα, and extends the sur-
vival of ovarian cancer [15]. Gemcitabine combined with
cisplatin chemotherapy significantly reduce the population
of CD4 + CD25 + FOXP3+ Treg in patients with non-
small cell lung cancer [8]. However, to date there is no dir-
ect evidence demonstrating the modulator roles of the
platinum-based chemical, CPA-7, on adaptive immunity.
To develop a feasible strategy for treatment of prostate
cancer with CPA-7, we initially evaluated its potential
toxicity in mice when administered at different concen-
tration. Assi et al. tested the potential toxicity of CPA-7
in a melanoma model [16]. They found there’s no obvi-
ous toxic effect on liver and spleen when CPA-7 was ad-
ministrated at 5 mg/kg. In our study, we used body
weight as evaluating index to find CPA-7 is safe to body
weight when the dose of a single injection is less than
1.5 mg/kg for long term administration. It is of note that
treatment with CPA-7 at 1.5 mg/kg significantly inhib-
ited growth of subcutaneously established prostate tu-
mors, but treatment with 0.75 mg/kg was ineffective.
Both doses of CPA-7 significantly prolonged both the
survival time and rate of the tumor bearing mice sug-
gesting that low-dose (0.75 mg/kg) CPA-7 may combat
tumors through other mechanisms than growth inhib-
ition. Indeed, we observed that whether in healthy or in
tumor bearing mice, a trend toward increased body
weight occurred in mice treated with 0.75 mg/kg CPA-7.
Therefore, we have determined the optimal and the
maximum dosage of CPA-7 in the RM-9 tumor model.
It has become evident that the immune surveillance
plays a pivotal role in controlling cancerous growth.
Some chemotherapeutic drugs not only directly inhibit
proliferation of tumor cells but also influence anticancer
immunity [26]. Platinum-based chemicals, either alone
or in combination with other agents, serve as direct
tumor inhibitors as well as immune modulators [22].
For example, oxaliplatin kills tumor cells directly but it
also initiates immunosuppressive pathways, resulting in
decreased activation of T cells by human plasmacytoid
dendritic cells (pDCs) [27]. These unfavorable effects of
platinum compounds may be related to the doses
employed for treatment, because low-dose cisplatin com-
bined with other modalities such as suicide gene therapy
improves tumor clearance by increasing the number of
tumor specific CD8+ T cells [28]. Our results clearly
showed a significant elevation in CD4+ and CD8+ cyto-
toxic T lymphocytes (CTL) and a reduction in CD4 +
CD25 + FOXP3+ Treg after treatment of mice with CPA-7.
Considering the Treg inhibiting function of CPA-7, the in-
crease of CD4+ population suggests that treatment with
CPA-7 efficiently promotes the anti antigen activity of
the immune system. Furthermore, down-regulation of
Treg cells indicates that in addition to immunostimula-
tion, CPA-7 may depress immunosuppressive pathways.
Altogether, our results demonstrate that CPA-7 treat-
ment is efficient in remodeling both immunostimula-
tion and immunosuppression processes, conferring an
enhanced immune activity against tumor recurrence
and distant metastasis. This notion is evidenced by the
significant low recurrence rate of the rechallenged tu-
mors in this study, supporting CPA-7 as a potential
synergistic pre-surgical or neo-adjuvant therapy for PC.
Our in vitro and in vivo results clearly demonstrated
that the anti-tumor effects of CPA-7 are closely correlated
with signal transducer and activator of transcription 3
(STAT3). STAT3 is a well known transcription factor that
plays key roles not only in tumor development and tumor
metastasis, but also in immune surveillance and immune
response [11, 14]. Therefore inhibiting or demolishing the
Fig. 4 CPA-7 effects on immune profile. CD4+ (a), CD8+ (b), and Treg (c) in spleens and Treg in tumor draining lymph nodes (TDLNs) (d) were
determined three days after CPA-7 treatment at indicated doses. Likewise, CD4+ (e), CD8+ (f), and Treg (g) in spleens and Treg in TDLNs (h) were
determined 12 days after CPA-7 treatment at indicated doses. n = 3 for each group. *, P < 0.05, **, P < 0.01, ***, P < 0.001 when compared with the
vehicle group
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expression of active STAT3 is of great interest for both
directly anti tumor treatment and tumor specific im-
munotherapy [11, 29, 30]. STAT3 promotes tumorigen-
esis by regulating the expression of various target
genes, including cell-cycle regulators, angiogenic fac-
tors and anti-apoptosis genes [14, 31, 32]. Retrospective
studies have established that STAT3 expression or
phospho-STAT3 (pSTAT3 or activated STAT3) are poor
prognostic markers for many cancers including PC
[33]. Inhibition of STAT3 activity limited PC cell motil-
ity, possibly via transcriptive regulation of NKX3.1 and
KLF4 gene expression by directly binding to both pro-
moters [16, 34]. In our study, CPA-7 treatment reduced
the phosphorylation of STAT3 resulting in a significant
retardation of tumor progression, which underscores
the pivotal role of STAT3 in PC treatment.
Among the immunosuppressive components that hin-
der the ability of the immune system to mount a suffi-
cient immune response, STAT3 has been shown to
function in the junction of several oncogenic and inflam-
matory pathways [35]. STAT3 is known to be activated
by several immunosuppressive cytokines commonly found
in the tumor microenvironment, such as IL-10, which, in
turn, further promotes the expression of these cytokines
through a positive feedback loop. Furthermore, STAT3 in-
hibits the expression of pro-inflammatory cytokines, such
as IL-12, and has been demonstrated to employ infiltrating
immune cells as a means of evading innate and adaptive
immunity [36]. In this study, we found that the phosphor-
ylation level of STAT3 strikingly decreased when the treat-
ment of CPA-7 was adopted. The depletion of pSTAT3, in
turn, led to a significant down-regulation of its transcrip-
tional activity. In addition to the in vitro cultured cells,
CPA-7 also inhibited the level of pSTAT3 in established
tumor tissue. pSTAT3 expression was particularly inhib-
ited in the tumor infiltrating region by CPA-7 treatment.
This inhibition by CPA-7 may lead to the down regulation
of FOXP3 and then account for the decreasing number of
Treg cells in the immune system, because activated STAT3
induces expression of FOXP3, an essential transcription
factor for Treg expansion [37]. In addition, our study fur-
ther demonstrated that the population of CD8+ cytotoxic
T cells was significantly expended after CPA-7 treatment,
in support of the recent studies that STAT3 inhibitors ab-
rogate immunosuppressive effects in PC patient-derived
MDSCs on CD8+ T cells and increase the ratio of tumor-
infiltrating CD8+ T cells to regulatory T cells, resulting in
CD8+ T cell dependent regression of cancer [9, 38].
Conclusion
In summary, our in vitro and in vivo studies demon-
strate that CPA-7 is a potential novel therapeutic for
treatment of prostate cancer, leading to decreased tumor
burden and increased survival. Administration of CPA-7
effectively inhibited the level of pSTAT3 in vivo. pSTAT3
depletion in the tumor tissue and in the spleen and
TDLN possibly accounted for reduction of tumor
growth, decrease of Treg and increase of CTL in the im-
mune system. These results indicate that CPA-7, in
addition to promoting immunostimulation, concomitantly
has an impact on immunosuppression. These beneficial
effects of CPA-7 may contribute to the resultant pro-
longed survival of mice with prostate cell induced tumors.
It is clear that comprehensive refinements and innovations
in cancer treatment strategies are needed to eradicate the
primary tumor while preventing tumor recurrence and
distant metastasis. Tumor immunotherapy holds great
promise, yet optimal strategies to balance the immunosti-
mulative and immunosuppressive responses must be de-
veloped to produce clinically significant therapeutic
benefits. Based on these concepts, in future studies we
propose a series of experiments both to fully elucidate
how STAT3 is involved in CPA-7 effects on the immune
response and to maximize the tumor inhibition effects of
CPA-7 for the clinical treatment of cancer.
Additional file
Additional file 1: Figure S1. In vivo level of pSTAT3 after CPA-7 treatment.
RM9 tumor tissues were collected 12 days after CPA-7 treatment.
Immunohistochemistry was performed and pSTAT3 positive cells were
stained in purple. Nuclei of pSTAT3 negative tumor cells were in blue.
(TIF 1104 kb)
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